Dean Capital Investments Management LLC Cuts Stake in Baxter International Inc (NYSE:BAX)

Dean Capital Investments Management LLC lowered its holdings in shares of Baxter International Inc (NYSE:BAX) by 5.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,012 shares of the medical instruments supplier’s stock after selling 373 shares during the quarter. Dean Capital Investments Management LLC’s holdings in Baxter International were worth $613,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. 1 North Wealth Services LLC bought a new position in Baxter International during the third quarter valued at approximately $27,000. Old North State Trust LLC bought a new position in Baxter International during the third quarter valued at approximately $31,000. Personal Wealth Partners bought a new position in Baxter International during the second quarter valued at approximately $29,000. TRUE Private Wealth Advisors bought a new position in Baxter International during the second quarter valued at approximately $29,000. Finally, Evolution Wealth Advisors LLC bought a new position in Baxter International during the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 83.19% of the company’s stock.

BAX has been the subject of a number of research reports. Deutsche Bank initiated coverage on Baxter International in a research note on Monday, October 21st. They set a “buy” rating and a $109.00 price target for the company. Raymond James increased their price target on Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Piper Jaffray Companies reissued a “buy” rating on shares of Baxter International in a research note on Tuesday, September 10th. BMO Capital Markets increased their price target on Baxter International to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Finally, Barclays set a $82.00 price target on Baxter International and gave the company a “hold” rating in a research note on Friday, July 26th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Baxter International currently has an average rating of “Buy” and an average target price of $90.14.

In other news, SVP Andrew Frye sold 3,332 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $88.00, for a total value of $293,216.00. Following the completion of the sale, the senior vice president now directly owns 16,391 shares of the company’s stock, valued at approximately $1,442,408. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James R. Gavin III sold 7,950 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $87.63, for a total value of $696,658.50. Following the completion of the sale, the director now directly owns 40,932 shares of the company’s stock, valued at $3,586,871.16. The disclosure for this sale can be found here. Insiders sold a total of 17,396 shares of company stock valued at $1,528,575 over the last ninety days. Corporate insiders own 0.70% of the company’s stock.

Shares of NYSE:BAX traded up $1.25 during trading on Tuesday, hitting $80.11. The company had a trading volume of 912,010 shares, compared to its average volume of 3,716,047. The stock has a market cap of $40.08 billion, a price-to-earnings ratio of 26.27, a price-to-earnings-growth ratio of 2.02 and a beta of 0.97. Baxter International Inc has a one year low of $61.40 and a one year high of $89.93. The company has a fifty day simple moving average of $83.72 and a two-hundred day simple moving average of $82.14. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: What does EPS mean?

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.